Offering Size Sample Clauses

Offering Size. The total offering size has been increased from $500 million to $875 million, which represents an increase of $375 million from the amount reflected in the Preliminary Prospectus Supplement.
View SourceView Similar (4)
Offering Size. The Issuers have increased the aggregate principal amount of the Notes offering from $1.75 billion to $2.2 billion. References in the Preliminary Offering Memorandum to the $1.75 billion aggregate principal amount of notes are hereby amended to reference the issuance of $2.2 billion aggregate principal amount of notes. Similar and corresponding changes will be made wherever applicable to the Preliminary Offering Memorandum, including as discussed below. The last paragraph under the row marked “Ranking” starting on page 7 of the Preliminary Offering Memorandum and each other location where similar language and such amounts may appear in the Preliminary Offering Memorandum is replaced in its entirety with the following “As of September 30, 2017, after giving effect to the offering of the notes, the 7-Eleven Transaction and the use of proceeds therefrom as described under “Use of Proceeds,” we would have had approximately $2.5 billion of debt outstanding, including $119 million of secured indebtedness under our Revolving Credit Facility (excluding approximately $9.0 million of letters of credit outstanding thereunder), and we would have had approximately $1.4 billion of remaining borrowing capacity under our Credit Agreement.” The second sentence under the row marked “Use of Proceeds” on page 9 is amended to read as follows: “We intend to use the net proceeds from this offering to redeem in full all outstanding Existing Senior Notes. The proceeds from the 7-Eleven Transaction will be used to (i) repay in full and terminate the Existing Term Loan, (ii) repay a portion of the outstanding borrowings under the Revolving Credit Facility, (iii) pay all closing costs and taxes in connection with the 7-Eleven Transaction, (iv) redeem all of our outstanding Series A Preferred Units, and (v) fund the repurchase of a portion of our outstanding common units.” The last paragraph under the row marked “Use of Proceeds” on page 9 is deleted in its entirety.
View SourceView Similar (3)
Offering Size. The Company has increased the offering of the Notes from $600 million aggregate principal amount to $750 million aggregate principal amount. Corresponding changes will be made wherever applicable to the Preliminary Prospectus Supplement, including as discussed below.
View SourceView Similar (3)
Offering Size. Up to US$75,150,000 (with a minimum offering of 9,000,000 Subscription Receipts for aggregate gross proceeds to the Company of US$40,050,000).
View Source
Offering Size. Disclosures set forth throughout the preliminary prospectus supplement are updated to reflect the increase in the size of the offering from an aggregate principal amount of Notes of $300,000,000 to $500,000,000. All figures presented as giving effect to the offering, including net proceeds from the offering and as adjusted cash and cash equivalents, total debt and total capitalization, excluding unamortized discount and premium, are increased accordingly to give effect to the increase in the offering size. ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM. America Management Companies, LLC AMG-▇▇▇▇▇▇▇▇, LLC AMG-Hillside, LLC AMG-▇▇▇▇▇▇▇▇▇▇, LLC AMG-▇▇▇▇▇, LLC AMG-Southern Tennessee, LLC AMG-Trinity, LLC Andalusia Physician Practices, LLC Ashland Physician Services, LLC Ashley Valley Medical Center, LLC Ashley Valley Physician Practice, LLC Athens Physicians Practice, LLC Athens Regional Medical Center, LLC Athens Surgery Center Partner, LLC ▇▇▇▇ ▇▇, LLC ▇▇▇▇ Physician Practices, Inc. Bolivar Physician Practices, LLC Bourbon Community Hospital, LLC Bourbon Physician Practice, LLC Brim Hospitals, Inc. Buffalo Trace Radiation Oncology Associates, LLC Care Health Company, Inc. Castleview Hospital, LLC Castleview Medical, LLC Castleview Physician Practice, LLC ▇▇▇▇▇ Regional Physician Practices, LLC Clinch Professional Physician Services, LLC Clinch Valley Physicians Associates, LLC Clinch Valley Medical Center, Inc. Clinch Valley Pulmonology, LLC Clinch Valley Urology, LLC Colorado Plains Physician Practices, LLC Community Hospital of Andalusia, Inc. Community Medical, LLC Community-Based Services, LLC ▇▇▇▇▇▇▇▇ Hospital, LLC ▇▇▇▇▇▇▇▇ PHO, LLC Danville Diagnostic Imaging Center, LLC Danville Physician Practices, LLC Danville Regional Medical Center School of Health Professions, LLC Danville Regional Medical Center, LLC DLP Partner, LLC DLP Partner Marquette, LLC DLP Partner MedWest, LLC DLP Partner Twin County, LLC Dodge City Healthcare Group, LLC Dodge City Healthcare Partner, Inc. Fauquier Partner, LLC Georgetown Community Hospital, LLC Georgetown Rehabilitation, LLC HCK ▇▇▇▇▇ Memorial, LLC HDP Andalusia, LLC HDP Georgetown, LLC Hillside Hospital, LLC Historic LifePoint Hospitals, Inc. HRMC, LLC HSCGP, LLC HSC Manager, LLC HST Physician Practic...
View Source
Offering Size. (a) The gross proceeds sought to be raised by the Corporation from the Rights Offering, assuming the exercise in full of the Rights, will be equal (as nearly as reasonably practicable) to $10,000,000 (the "Offering Size"). (b) The aggregate number of Rights Units (as nearly as practicable) which are issuable will be determined by dividing the Offering Size by the Subscription Price, as determined at the date of filing the Rights Offering Documents (the "Aggregate Rights Units"), with each holder of Shares at the Record Date receiving one Right per Share. Each Right shall entitle the holder thereof to subscribe for the number of Rights Units equal to the Aggregate Rights Units divided by the number of Shares outstanding on the date of filing the Rights Offering Documents, rounded to three decimal places (the "Rights Offering Ratio"), provided that if any Shares are issued prior to the Record Date (where such Shares are not already included in the determination of the Rights Offering Ratio), the Rights Offering Ratio will remain fixed as determined in the Rights Offering Documents and consequently, the number of Rights issued and the Aggregate Rights Units will be increased.
View Source
Offering Size. The Issuer has increased the offering of the Notes from $325 million aggregate principal amount (or $375 million if the over-allotment option to purchase additional Notes is exercised in full) to $350 million aggregate principal amount (or $400 million if the over-allotment option to purchase additional Notes is exercised in full). Corresponding changes will be made wherever applicable in the Preliminary Offering Memorandum, including as discussed below. In particular, at December 31, 2012, on an as adjusted basis after giving effect to this offering, we would have had, on a consolidated basis, approximately $1,578.7 million of outstanding liabilities (or $1,628.9 million if the initial purchaser exercises its over-allotment option in full) (which amounts, with respect to the notes offered hereby and our $300.0 million 2.50% Convertible Notes, reflect the face amount of such notes). In addition, we would have had, on a consolidated basis, up to $100.0 million available under the revolving financing facility of Variable Funding Notes. Substantially all of our liabilities (other than the 2.50% Convertible Notes and the notes offered hereby) are obligations of our subsidiaries, including the Senior Secured Notes, the Variable Funding Notes and the Ecko Note. The notes will be structurally subordinated to all such existing and future indebtedness and other liabilities of our subsidiaries. The “Capitalization” section on pages 37-38 of the Preliminary Offering Memorandum is hereby replaced in its entirety with the “Capitalization” section set forth below: The following table sets forth our consolidated cash and cash equivalents and capitalization as of December 31, 2012: • on an actual basis; and • on an as adjusted basis to reflect the issuance and sale of notes and the application of the net proceeds therefrom to pay the $23.1 million net cost of the convertible note hedge transaction and warrant transaction and to repurchase approximately 2.96 million shares of our common stock concurrently with this offering in privately negotiated transactions effected through Barclays Capital Inc. for an aggregate purchase price of approximately $69.0 million (the price per share of the common stock repurchased in such transactions is equal to the last reported sale price of our common stock on the NASDAQ Global Market on March 12, 2013, which equals $23.29 per share of our common stock). This table should be read in conjunction with “Use of Proceeds” and our consolidated...
View Source
Offering Size. The aggregate principal amount of Notes in the offering has been increased to $350,000,000, which represents an increase of $50,000,000 from the amounts reflected in the Preliminary Prospectus Supplement. As a result, all information (including financial information) presented in the Preliminary Prospectus Supplement is deemed to have changed to the extent affected by the changes described herein.
View Source
Offering Size. The Issuers have increased the aggregate principal amount of the offering from $250.0 million to $300.0 million. References in the Preliminary Offering Memorandum to the $250.0 million aggregate principal amount of new notes are hereby amended to reference the issuance of $300.0 million aggregate principal amount of new notes. The net proceeds from the increased amount of the offering will be used to repay additional amounts of existing indebtedness outstanding under our Credit Facility. *A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time. Any disclaimer or other notice that may appear below is not applicable to this communication and should be disregarded. Such disclaimer or notice was automatically generated as a result of this communication being sent by Bloomberg or another email system. In connection with offers and sales of Securities outside the United States:
View Source

Related to Offering Size

  • Limitations on Offering Size Under no circumstances shall the Company cause or request the offer or sale of any Placement Shares if, after giving effect to the sale of such Placement Shares, the aggregate gross sales proceeds of Placement Shares sold pursuant to this Agreement would exceed the lesser of (A) together with all sales of Placement Shares under this Agreement, the Maximum Amount, (B) the amount available for offer and sale under the currently effective Registration Statement and (C) the amount authorized from time to time to be issued and sold under this Agreement by the Company’s board of directors, a duly authorized committee thereof or a duly authorized executive committee, and notified to the Agent in writing. Under no circumstances shall the Company cause or request the offer or sale of any Placement Shares pursuant to this Agreement at a price lower than the minimum price authorized from time to time by the Company’s board of directors, a duly authorized committee thereof or a duly authorized executive committee, and notified to the Agent in writing. Further, under no circumstances shall the Company cause or permit the aggregate offering amount of Placement Shares sold pursuant to this Agreement to exceed the Maximum Amount.

  • Class Size GRADE LOADING RATIO MAXIMUM CLASS SIZE 7.01 Students shall not be assigned to any class which has reached the maximum class size except as provided within this article. 7.02 The site/program administrator is required to discuss class size at a member’s request if the member’s class exceeds the loading ratio. 7.03 Instrumental and choral music classes may exceed the maximums by 1.5 times. Physical education classes may exceed the maximum by 1.35. 7.04 The site/program administrator shall make a reasonable effort to schedule English composition classes in grades 9-12 with a maximum of 29 students. 7.05 The site/program administrator shall make a reasonable effort to schedule combination classes in which students are assigned to more than one grade level K-3 or 3-4 with a maximum of 29 students and 4-6 with a maximum of 30 students. 7.06 The District will make a reasonable effort, within the financial constraints of the District, to reduce class size maximums in those classes into which special education students are integrated, in remedial classes, and in high school composition classes. 7.07 Special Education Classes shall not exceed the maximum cited in the law. 7.07.1 SDC Class Size SDC 7-12 non-severe caseload maximum shall be 26 beginning July 2002; RSP caseload shall be 28; a. The District shall make a reasonable effort to equalize class sizes as determined by the class roster throughout the District within the grade levels and programs consistent with the needs of the students as set forth in his/her IEP and the unique features of each group. “Reasonable effort” may include, but is not limited to include, busing students on a voluntary basis to other sites, moving students to other classes at that site, or adding an instructional aide. b. Except for Hearing Impaired, Visually Handicapped Preschool, SED, and ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ Center classes, average class size within the SDC program in the District shall not exceed 12 students. The class size for any specific class shall not exceed 17 students. In Hearing Impaired, Visually Handicapped Preschool, SED, and ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ Center classes, the District class size average shall not exceed 10, and any individual class shall not exceed 14. c. The District and the Association agree to establish a Special Education/General Education Oversight Committee composed of seven members of which a majority are teachers. The committee shall recognize that consensus is the preferable decision making process. In cases where consensus is not achievable, all decisions and recommendations shall require five (5) votes. The oversight committee shall be established to oversee, guide, and facilitate the following initiatives: i. Two-year K-12 pilot program that shall include no more than six

  • Offering Price Shares of any class of the Fund offered for sale by you shall be offered for sale at a price per share (the "offering price") approximately equal to (a) their net asset value (determined in the manner set forth in the Fund's charter documents) plus (b) a sales charge, if any and except to those persons set forth in the then-current prospectus, which shall be the percentage of the offering price of such Shares as set forth in the Fund's then-current prospectus. The offering price, if not an exact multiple of one cent, shall be adjusted to the nearest cent. In addition, Shares of any class of the Fund offered for sale by you may be subject to a contingent deferred sales charge as set forth in the Fund's then-current prospectus. You shall be entitled to receive any sales charge or contingent deferred sales charge in respect of the Shares. Any payments to dealers shall be governed by a separate agreement between you and such dealer and the Fund's then-current prospectus.

  • Minimum Amounts and Maximum Number of Tranches All borrowings, prepayments, conversions and continuations of Loans hereunder and all selections of Interest Periods hereunder shall be in such amounts and be made pursuant to such elections so that, after giving effect thereto, the aggregate principal amount of the Loans comprising each Eurodollar Tranche shall be equal to $10,000,000 or a whole multiple of $1,000,000 in excess thereof. In no event shall there be more than five Eurodollar Tranches outstanding at any time.

  • Unsubscribe or Opt-Out All users and visitors to our website have the option to discontinue receiving communications from us by way of email or newsletters. To discontinue or unsubscribe from our website please send an email that you wish to unsubscribe to ▇▇▇▇@▇▇▇▇▇▇▇▇.▇▇▇. If you wish to unsubscribe or opt-out from any third-party websites, you must go to that specific website to unsubscribe or opt- out. ACROSS SPECIALTY PHARMACY will continue to adhere to this Policy with respect to any personal information previously collected.